← SynDRA
IDELALISIB
SynDRA canonical compound SYN0034405 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | PIK3CG |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
| Indication | chronic lymphocytic leukemia (CLL) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- PIK3CD
- PIK3CG
- PIK3CA
- PIK3CB
- CCL3
- CCL4
- PIK3C3
- PRKDC
- Pik3cg
Mechanisms of action (all sources)
- PI3K inhibitor
- PIK3CD INHIBITOR
- PI3-kinase p110-delta subunit inhibitor
Drug classes
- Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Kinase Inhibitor
- Cytochrome P450 3A Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- CAL-101
- zydelig
- GS-1101
- GS-11CAL-101
- CAL-101 (GS-1101)
- IDELALISIBCT-CAL101IDEALISIBCAL-101CAL 101GS-1101GS 1101ZYDELIGA-1138CAL101
- Zydelig
- CAL 101
- CAL101
- (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
- UNII-YG57I8T5M0
- CAL-101 (Idelalisib, GS-1101)
- YG57I8T5M0
- CHEMBL2216870
- CHEBI:82701
- 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one
- AK145603
- (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
- 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE
- GS 1101
- Idelalisib (CAL-101)
- Idelalisib; CAL-101
- 5-fluoro-3-phenyl-2-((1s)-1-(9h-purin-6-ylamino)propyl)-4(3h)-quinazolinone
- 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one
- 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one
- 5-Fluoro-3-Phenyl-2-[(1s)-1-(7h-Purin-6-Ylamino)propyl]quinazolin-4(3h)-One
- Idelalisib [INN]
- Idelalisib [USAN:INN]
- Idealisib
- Zydelig (TN)
- IDELALISIB [MI]
- IDELALISIB [JAN]
- IDELALISIB [USAN]
- IDELALISIB [VANDF]
- IDELALISIB [WHO-DD]
- MLS006010985
- Idelalisib (JAN/USAN/INN)
- SCHEMBL356400
Reported adverse events
- Infection
- Neutropenia
- Pneumonitis
- Rash
- Abdominal pain
- Colitis
- Hepatotoxicity
- Hypersensitivity
- Lymphoma
- Pneumonia
- Sepsis
- Stevens-Johnson syndrome
Look up IDELALISIB in the interactive SynDRA portal →